Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jul;165(7):1633-1639.
doi: 10.1007/s00705-020-04639-x. Epub 2020 Apr 30.

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

Ebada Mohamed Said  1 , Badawy A Abdulaziz  1 , Mohamed El Kassas  2 , Ibrahim Hussein El Attar  1 , Mohammed Emadeldeen  3 , Sherief M Abd-Elsalam  4
Affiliations
Clinical Trial

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

Ebada Mohamed Said et al. Arch Virol. 2020 Jul.

Retraction in

Abstract

The aim of this work was assessment of the efficacy and tolerability of two different regimens for retreatment of hepatitis C virus (HCV) patients who failed to respond to SOF/DCV-based therapy. This prospective study included 104 HCV patients who failed to respond to SOF/DCV-based therapy. Patients were randomly allocated to two groups. Efficacy and tolerability were assessed. The 12-week sustained virological response (SVR12) rates were 96% and 94.4% in groups B and A, respectively, with no significant difference (p = 1.000). Most adverse events reported were mild to moderate, with no deaths during the study. Multi-target direct-acting antiviral (DAA) combinations are efficient for retreatment of HCV patients after failure of SOF/DCV-based therapy in real-world management.ClinicalTrials.gov identifier: NCT02992457.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Andrea L (2015) Global control of hepatitis C virus. Science 349:790–791 - DOI
    1. Jefferies M, Rauff B, Rashid H et al (2018) Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 6(13):589–599 - DOI - PubMed - PMC
    1. Ahmed OA, Kaisar HH, Badawi R et al (2018) Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 1(11):295–298 - DOI
    1. Ahmed OA, Elsebaey MA, Fouad MHA et al (2018) Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist 28(11):441–445 - DOI
    1. Ahmed OA, Safwat E, Khalifa MO et al (2018) Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village. Int J Hepatol 2018:9616234 - DOI - PubMed - PMC

MeSH terms

Associated data

LinkOut - more resources